AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
The ATP-gated P2X(1) ion channel acts as a positive regulator of platelet responses to collagen
Authors: Oury, C Toth-Zsamboki, E Thys, C Tytgat, J Vermylen, J Hoylaerts, MF
Citation: C. Oury et al., The ATP-gated P2X(1) ion channel acts as a positive regulator of platelet responses to collagen, THROMB HAEM, 86(5), 2001, pp. 1264-1271
The P2Y(1) receptor antagonist adenosine-2 ',5 '-diphosphate non-selectively antagonizes the platelet P2X(1) ion channel
Authors: Toth-Zsamboki, E Oury, C Tytgat, J Vermylen, J Hoylaerts, MF
Citation: E. Toth-zsamboki et al., The P2Y(1) receptor antagonist adenosine-2 ',5 '-diphosphate non-selectively antagonizes the platelet P2X(1) ion channel, THROMB HAEM, 86(5), 2001, pp. 1338-1339
Genetic variation of the extra-large stimulatory G protein alpha-subunit leads to Gs hyperfunction in platelets and is a risk factor for bleeding
Authors: Freson, K Hoylaerts, MF Jaeken, J Eyssen, M Arnout, J Vermylen, J Van Geet, C
Citation: K. Freson et al., Genetic variation of the extra-large stimulatory G protein alpha-subunit leads to Gs hyperfunction in platelets and is a risk factor for bleeding, THROMB HAEM, 86(3), 2001, pp. 733-738
Congenital disorders of glycosylation type Ia and IIa are associated with different primary haemostatic complications
Authors: Van Geet, C Jaeken, J Freson, K Lenaerts, T Arnout, J Vermylen, J Hoylaerts, MF
Citation: C. Van Geet et al., Congenital disorders of glycosylation type Ia and IIa are associated with different primary haemostatic complications, J INH MET D, 24(4), 2001, pp. 477-492
Mouse carotid artery ligation induces platelet-leukocyte-dependent luminalfibrin, required for neointima development
Authors: Kawasaki, T Dewerchin, H Lijnen, HR Vreys, I Vermylen, J Hoylaerts, MF
Citation: T. Kawasaki et al., Mouse carotid artery ligation induces platelet-leukocyte-dependent luminalfibrin, required for neointima development, CIRCUL RES, 88(2), 2001, pp. 159-166
Increased mortality with long-term platelet glycoprotein IIb/IIIa antagonists: An explanation?
Authors: Vermylen, J Hoylaerts, M Arnout, J
Citation: J. Vermylen et al., Increased mortality with long-term platelet glycoprotein IIb/IIIa antagonists: An explanation?, CIRCULATION, 104(20), 2001, pp. E109-E109
Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation
Authors: Freson, K Devriendt, K Matthijs, G Van Hoof, A De Vos, R Thys, C Minner, K Hoylaerts, MF Vermylen, J Van Geet, C
Citation: K. Freson et al., Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation, BLOOD, 98(1), 2001, pp. 85-92
ADP receptors in platelet activation and aggregation
Authors: Hoylaerts, MF Oury, C Toth-Zsamboki, E Vermylen, J
Citation: Mf. Hoylaerts et al., ADP receptors in platelet activation and aggregation, PLATELETS, 11(6), 2000, pp. 307-309
Drugs affecting blood coagulation, fibrinolysis, and hemostasis
Authors: Peerlinck, K Vermylen, J
Citation: K. Peerlinck et J. Vermylen, Drugs affecting blood coagulation, fibrinolysis, and hemostasis, SIDE EFFECT, 23, 2000, pp. 377-379
Humanized severe combined immunodeficient mice as a potential model for the study of tolerance to factor VIII
Authors: Vanzieleghem, B Gilles, JG Desqueper, B Vermylen, J Saint-Remy, JM
Citation: B. Vanzieleghem et al., Humanized severe combined immunodeficient mice as a potential model for the study of tolerance to factor VIII, THROMB HAEM, 83(6), 2000, pp. 833-839
A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue
Authors: Oury, C Toth-Zsamboki, E Van Geet, C Thys, C Wei, L Nilius, B Vermylen, J Hoylaerts, MF
Citation: C. Oury et al., A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue, J BIOL CHEM, 275(30), 2000, pp. 22611-22614
A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIIIC1 domain reduce factor VIII binding to von Willebrand factor
Authors: Jacquemin, M Lavend'homme, R Benhida, A Vanzieleghem, B d'Oiron, R Lavergne, JM Brackmann, HH Schwaab, R VandenDriessche, T Chuah, MKL Hoylaerts, M Gilles, JGG Peerlinck, K Vermylen, J Saint-Remy, JMR
Citation: M. Jacquemin et al., A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIIIC1 domain reduce factor VIII binding to von Willebrand factor, BLOOD, 96(3), 2000, pp. 958-965
Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysisduring acute arterial thrombosis in mice
Authors: Kawasaki, T Dewerchin, M Lijnen, HR Vermylen, J Hoylaerts, MF
Citation: T. Kawasaki et al., Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysisduring acute arterial thrombosis in mice, BLOOD, 96(1), 2000, pp. 153-160
A human antibody directed to the factor VIIIC1 domain inhibits factor VIIIcofactor activity and binding to von Willebrand factor
Authors: Jacquemin, M Benhida, A Peerlinck, K Desqueper, B Elst, LV Lavend'homme, R d'Oiron, R Schwaab, R Bakkus, M Thielemans, K Gilles, JG Vermylen, J Saint-Remy, JM
Citation: M. Jacquemin et al., A human antibody directed to the factor VIIIC1 domain inhibits factor VIIIcofactor activity and binding to von Willebrand factor, BLOOD, 95(1), 2000, pp. 156-163
Lupus anticoagulants: Mechanistic and diagnostic considerations
Authors: Arnout, J Vermylen, J
Citation: J. Arnout et J. Vermylen, Lupus anticoagulants: Mechanistic and diagnostic considerations, HUGHES SYNDROME: ANTIPHOSPHOLIPID SYNDROME, 2000, pp. 225-237
Acute myocardial infarction following administration of recombinant activated factor VII (Novo seven) in a patient with haemophilia A and inhibitor
Authors: Peerlinck, K Vermylen, J
Citation: K. Peerlinck et J. Vermylen, Acute myocardial infarction following administration of recombinant activated factor VII (Novo seven) in a patient with haemophilia A and inhibitor, THROMB HAEM, 82(6), 1999, pp. 1775-1776
Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes
Authors: Gilles, JGG Lavend'homme, R Peerlinck, K Jacquemin, MG Hoylaerts, M Jorieux, S Mazurier, C Vermylen, J Saint-Remy, JMR
Citation: Jgg. Gilles et al., Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes, THROMB HAEM, 82(1), 1999, pp. 40-45
Lupus anticoagulant testing in Europe: An analysis of results from the first European concerted action on thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta(2)-glycoprotein I
Authors: Arnout, J Meijer, P Vermylen, J
Citation: J. Arnout et al., Lupus anticoagulant testing in Europe: An analysis of results from the first European concerted action on thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta(2)-glycoprotein I, THROMB HAEM, 81(6), 1999, pp. 929-934
Lupus anticoagulant: Influence on the international normalized ratio
Authors: Arnout, J Vermylen, J
Citation: J. Arnout et J. Vermylen, Lupus anticoagulant: Influence on the international normalized ratio, THROMB HAEM, 81(5), 1999, pp. 847-849
A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic
Authors: Kawasaki, T Kaida, T Arnout, J Vermylen, J Hoylaerts, MF
Citation: T. Kawasaki et al., A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic, THROMB HAEM, 81(2), 1999, pp. 306-311
Arterial occlusion and thrombus aspiration after total knee arthroplasty
Authors: Bellemans, J Stockx, L Peerlinck, K Vermylen, J Lacroix, H Suy, R
Citation: J. Bellemans et al., Arterial occlusion and thrombus aspiration after total knee arthroplasty, CLIN ORTHOP, (366), 1999, pp. 164-168
Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress
Authors: Theilmeier, G Lenaerts, T Remacle, C Collen, D Vermylen, J Hoylaerts, MF
Citation: G. Theilmeier et al., Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress, BLOOD, 94(8), 1999, pp. 2725-2734
Antifactor VIII antibody inhibiting allogeneic but not antologous factor VIII in patients with mild hemophilia A
Authors: Peerlinck, K Jacquemin, MG Arnout, J Hoylaerts, MF Gilles, JGG Lavend'homme, R Johnson, KM Freson, K Scandella, D Saint-Remy, JMR Vermylen, J
Citation: K. Peerlinck et al., Antifactor VIII antibody inhibiting allogeneic but not antologous factor VIII in patients with mild hemophilia A, BLOOD, 93(7), 1999, pp. 2267-2273
Prostanoids for chronic critical leg ischemia - A randomized, controlled, open-label trial with prostaglandin E-1
Authors: Belgrano, EA Guala, A Mazzucchetti, S Marinoni, V Calzoni, D Bedoni, P Confalonieri, MA Agus, GB Mondani, P De Angelis, R Biasi, GM Piglionica, MR Abbritti, F Agrifoglio, G Costantini, A Della Vedova, MR Miglierina, L Marrocu, R Bragherio, G Zanoni, CE Borin, F Alderi, G Emanuelli, G Colzani, M Ponti, GB Berra, S Bevilacqua, A Bocca, M Invernizzi, C De Angelis, E Tacconi, A D'Angelo, F Vaghi, M Arzini, A Boccalon, L Losapio, GM Ambrosi, R Briolini, F Inzoli, MR Lombardi, G Tarantola, P Zocca, N Tenchini, P Fontanili, M Guidetti, D Pedeferri, G Bordoni, MC Catalano, A Visconti, W Vedovato, F Zucchella, M Bon, GB Busetto, MT Zambon, C Carlassara, GB Zambelli, V Barbato, O Mazzilli, G Lino, M Pavan, S Pagnan, A Visona, A Perissinotto, C Tonietto, G Michelet, I Agresta, F Favretti, F Burigo, E De Lazzer, L Giansante, C Fiotti, N Grego, S Mozzon, L Gonano, N Pfeiffer, P Petrilli, GL Puzzo, A Baldino, G Podesta, A Guastini, A Traversaro, A Zinicola, N Baglietto, F Arnuzzo, L De Fabritiis, A Filippini, M Ferrari, F Martini, L Testoni, P Accorsi, F Maurizi, P Evangelisti, G Roffi, A Marzara, G Fini, C Coppi, G Camparini, S Tusini, N Tuscano, G Lonardi, R Rozza, A Botta, GC Villani, LG Pavarini, E Campanella, P Moratti, A Ieran, M Bertini, D Pratesi, C Narcetti, S Corsi, C Pollastri, M Marrapodi, E Melillo, E Iabichella, ML Setacci, C Sozio, G Cao, P Verzini, F Mannarino, E Pasqualini, L Vaudo, G Alo, F Ioannidis, G Spartera, C Marino, G Bafile, G Anselmi, E Maniscalco, G Longo, P Di Giovanni, V Colli, R Bracale, G Bernardo, B Perretti, B Valitutti, P Vigliotti, G Rolli, F Pascali, M Sabella, G Grilli, M Correra, M Palese, E Florena, M Cassina, I Cumbo, P Comande, C Notarbartolo, A Novo, S Belvedere, M Caruso, R Verghi, F Romeo, S Cormaci, OF Binaghi, F Fronteddu, P Cannas, F de Gaetano, G Tognoni, G Avanzini, F Bertele, V Di Giulio, P Pangrazzi, J Roncaglioni, MC Colombo, F Terzian, E Coccheri, S Del Favero, A Geraci, E Janzon, L Vermylen, J Baldino, G Beghi, E Coen, D Nardella, L Turazza, F
Citation: Ea. Belgrano et al., Prostanoids for chronic critical leg ischemia - A randomized, controlled, open-label trial with prostaglandin E-1, ANN INT MED, 130(5), 1999, pp. 412
Optimal care of inhibitor patients during surgery
Authors: Vermylen, J Peerlinck, K
Citation: J. Vermylen et K. Peerlinck, Optimal care of inhibitor patients during surgery, EUR J HAEMA, 61, 1998, pp. 15-17
Risultati: 1-25 | 26-26